Amgen, Inc. vs Coursera Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Coursera Inc trades at $5.65 (market cap $1.50B). The key difference: Amgen, Inc. is far larger — about 149.4× Coursera Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| AMGN | COUR | |
|---|---|---|
Market Cap | $224.14B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $12.20 |
52-Week Low | $271.18 | $5.09 |
Enterprise Value | $267.45B | $759.54M |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →